Please login to the form below
Hisun
This page shows the latest Hisun news and features for those working in and with pharma, biotech and healthcare.
Pfizer cuts 2013 forecast after weak first quarter
of $490m from the transfer of certain product rights to its China-based joint venture with Hisun.
Latest news
-
Pharma's biggest news stories in 2011
and Pfizer announced plans to work with both Zhejiang Hisun Pharmaceuticals and Shanghai Pharmaceuticals Co.
-
Pfizer/Hisun to collaborate in China
Pfizer has announced it is to work with Zhejiang Hisun Pharmaceuticals to develop and market generic drugs in China. ... Hua Bai, CEO and president of Hisun Pharmaceuticals, stated that such deals were the way forward for the company.
-
News in brief, July 04, 2007
Hisun Pharma to form JV with Spanish company. Zhejiang Hisun Pharmaceutical, which is one of China's biggest active pharmaceutical ingredient producers, has signed a letter of intent with an unnamed
More from news
Approximately 0 fully matching, plus 4 partially matching documents found.
Latest Intelligence
-
Pharma deals during January 2013
Watson continues to extend its women's health franchise. Picking up on several of last year's deal trends, Zhejiang Hisun reported the closure of an exclusive option to access ... So the deployment of an option excluding third party access in this case
-
Biosimilars in China
Several joint venture deals between MNCs and Chinese players have been sealed recently: Hisun with Pfizer, Simcere with Merck and Fosun with Lonza.
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- World Health Organization releases latest set of COVID-19 guidelines
- BeiGene’s Brukinsa receives FDA approval for chronic lymphocytic leukaemia
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- Eli Lilly announces $450m investment in US manufacturing site
- Europe’s cancer community publishes new report on transforming patient care
- EU outlines measures to mitigate antibiotic shortage across Europe
- Innovative Trials comments on extra funding to increase access to clinical trials for cancer patients
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- JCVI recommends autumn COVID-19 vaccine booster for those at highest risk
- MIT researchers develop AI model to detect future lung cancer risk
- Merging global and local pharmacovigilance operations into a successful integrated approach
- Diversifying Healthcare AI with Federated Learning
- FDA and CDC investigate potential safety concern for Pfizer/BioNTech’s COVID-19 vaccine
- World Health Organization releases latest set of COVID-19 guidelines
- AbbVie and Eli Lilly leave UK’s voluntary drug pricing agreement
- EU to revise pharmaceuticals law amid antibiotic shortages
- European MPs call for urgent action against antimicrobial resistance
- The role of medical communications in building credibility for healthtech
PMHub
11 London
We live in a hyper-connected world. This has clear benefits for the health of our communities, our businesses and our...
Latest intelligence
- Virtual Steering Committee & Peer Influence Program
- In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
- Meeting healthcare’s rising challenges
- The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
- Report gives insights to address gaps in HCP engagement
- How does Pharma-HCP engagement need to evolve in today's digital landscape?...
